Please ensure Javascript is enabled for purposes of website accessibility

Why Opko Health's Shares Fell 20% in January

By Todd Campbell – Feb 2, 2016 at 2:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A broad-based sell off in biotech caused shares in this emerging healthcare play to tumble.

Source: Opko Health,

What: Despite outlining plans for the future at J.P. Morgan's annual healthcare conference early last month, shares in Opko Health, (OPK -0.53%) slid 20% in January, according to S&P Capital IQ.

So what: On January 12, Opko Health offered up insight into its business strategy, including an update on a slate of drugs in various stages of development and how it hopes to leverage last year's acquisition of the specialty lab services company Bio-Reference Labs.

Here are the highlights:

  • In November, Tesaro (NASDAQ: TSRO) launched Varubi an anti-nausea cancer drug it licensed from Opko Health. Varubi competes in a $1 billion market and Opko Health can collect $95 million in milestones, plus double digit royalties on sales.
  • On March 29, the FDA is expected to decide whether or not to approve Opko Health's Rayaldee, a vitamin D prohormone for use in chronic kidney disease patients. Opko Health estimates this market to be worth as much as $12 billion.
  • In the second half of the year, Opko Health expects to report phase 3 data for hGH-CTP, a human growth hormone that it's developing in collaboration with Pfizer Inc. (PFE -1.10%). If approved, Opko Health could collect up to $275 million in milestone payments plus royalties from Pfizer; and
  • This year will mark the first full year owning Bio-Reference Labs, a specialty lab with over $800 million in fiscal '14 sales and valuable partnerships with insurers and doctors that could allow it to boost demand for its 4Kscore prostate cancer test.

Now what: It looks to be a busy year for Opko Health and last month's sell-off shows that many investors aren't convinced (yet) that all that activity will pan out and justify the company's multi-billion dollar market cap.

Philip Frost, however, is one investor who is unwavering in his optimism. Frost, one of the most well-known biotech billionaires and the former CEO of Teva Pharmaceuticals, is Opko Health's CEO and its biggest shareholder. Importantly, he's been steadily buying Opko Health shares for more than a year.

Because Frost has achieved notable success in the past, it may be worth giving him and Opko Health the benefit of the doubt this time around too. If so, then picking up shares at these levels may prove profit-friendly.

  

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.08 (-1.10%) $0.49
OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
OPK
$1.88 (-0.53%) $0.01
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.90 (-1.98%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.